FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013582503> ?p ?o ?g. }

• W3013582503 abstract "Introduction: Brain metastatic disease (BMD) is attributed to significant mortality and morbidity in breast cancer patients. Strict policing of molecular traffic across the blood-brain barrier (BBB) precludes brain parenchymal penetration of most small molecule drugs, chemotherapy included. Consequently, the treatment of BMD remains difficult, particularly if the BBB remains intact during disease progression. Artemisinin has been efficacious in treating multi-drug resistant cerebral malaria likely indicative of an ability to traverse the BBB. Thus, Artemisinin may be able to modulate the restrictive nature of the BBB and provide a potential adjunctive therapy to established drug therapy in the treatment of BMD. Emerging evidence suggests that Artemisinin itself may harbour potent anti-cancer properties. Aim: To investigate in vitro the effect on barrier function in particular paracellular permeability of brain vascular endothelial cells compared to non-brain vascular endothelial cells when treated with Artemisinin. Materials and Methods: Inter-individual BBB differences were modelled using the human brain vascular endothelial cell lines hCMEC-D3, TY09 and TY10. In addition to the brain cell lines, a HUVEC cell line was treated with incremental concentrations of artemisinin. Adhesion, migration and electrical resistance across cellular monolayers were quantified using Electric Cell-Substrate Impedance Sensing (ECIS). Trans- Endo/Epithelial Resistance (TEER) and Paracellular Permeability (PCP) were used to assess barrier function. Immunofluorescence was used to qualitatively assess tight junction (TJ) integrity of all cell lines. RNAseq was used to determine changes in message after treatment with Artemisinin in all 4 cell lines. Results: A significant reduction in electrical resistance across all cell lines was observed when treated with 1mM Artemisinin and may be suggestive of a cytotoxic concentration. In comparison when treated with 0.01mM Artemisinin the electrical resistance decreased which could suggest restrictive barrier properties were enhanced, in addition evidencing Artemisinin may exhibit biphasic activity. The reduction in electrical resistance across the brain endothelial cell lines was significant (p Conclusion: The results demonstrate that Artemisinin may have the capacity to transiently increase or decrease the permeability of the BBB. Therefore, Artemisinin may have a role in facilitating drug delivery to the cerebral parenchyma providing potential therapeutic benefit for the treatment of BMD or other related neurological conditions difficult to treat due to the BBB. Citation Format: Emily Appadurai, Fiona Ruge, Andrew Sanders, Wen G Jiang, Tracey A. Martin. Controlling tight junctions in the blood brain barrier (BBB) with artemisinin as a potential adjuvant in the treatment of metastatic disease [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-20-04." @default.
• W3013582503 created "2020-04-03" @default.
• W3013582503 creator A5006559236 @default.
• W3013582503 creator A5017993198 @default.
• W3013582503 creator A5066459661 @default.
• W3013582503 creator A5076724878 @default.
• W3013582503 creator A5085688751 @default.
• W3013582503 date "2020-02-14" @default.
• W3013582503 modified "2023-10-16" @default.
• W3013582503 title "Abstract P2-20-04: Controlling tight junctions in the blood brain barrier (BBB) with artemisinin as a potential adjuvant in the treatment of metastatic disease" @default.
• W3013582503 doi "https://doi.org/10.1158/1538-7445.sabcs19-p2-20-04" @default.
• W3013582503 hasPublicationYear "2020" @default.
• W3013582503 type Work @default.
• W3013582503 sameAs 3013582503 @default.
• W3013582503 citedByCount "0" @default.
• W3013582503 crossrefType "proceedings-article" @default.
• W3013582503 hasAuthorship W3013582503A5006559236 @default.
• W3013582503 hasAuthorship W3013582503A5017993198 @default.
• W3013582503 hasAuthorship W3013582503A5066459661 @default.
• W3013582503 hasAuthorship W3013582503A5076724878 @default.
• W3013582503 hasAuthorship W3013582503A5085688751 @default.
• W3013582503 hasConcept C113045295 @default.
• W3013582503 hasConcept C120882062 @default.
• W3013582503 hasConcept C123012128 @default.
• W3013582503 hasConcept C126322002 @default.
• W3013582503 hasConcept C177779419 @default.
• W3013582503 hasConcept C202751555 @default.
• W3013582503 hasConcept C203014093 @default.
• W3013582503 hasConcept C2776120307 @default.
• W3013582503 hasConcept C2778048844 @default.
• W3013582503 hasConcept C2778371730 @default.
• W3013582503 hasConcept C2778402981 @default.
• W3013582503 hasConcept C41625074 @default.
• W3013582503 hasConcept C502942594 @default.
• W3013582503 hasConcept C529278444 @default.
• W3013582503 hasConcept C54355233 @default.
• W3013582503 hasConcept C55493867 @default.
• W3013582503 hasConcept C60903277 @default.
• W3013582503 hasConcept C71924100 @default.
• W3013582503 hasConcept C86803240 @default.
• W3013582503 hasConcept C95444343 @default.
• W3013582503 hasConcept C98274493 @default.
• W3013582503 hasConceptScore W3013582503C113045295 @default.
• W3013582503 hasConceptScore W3013582503C120882062 @default.
• W3013582503 hasConceptScore W3013582503C123012128 @default.
• W3013582503 hasConceptScore W3013582503C126322002 @default.
• W3013582503 hasConceptScore W3013582503C177779419 @default.
• W3013582503 hasConceptScore W3013582503C202751555 @default.
• W3013582503 hasConceptScore W3013582503C203014093 @default.
• W3013582503 hasConceptScore W3013582503C2776120307 @default.
• W3013582503 hasConceptScore W3013582503C2778048844 @default.
• W3013582503 hasConceptScore W3013582503C2778371730 @default.
• W3013582503 hasConceptScore W3013582503C2778402981 @default.
• W3013582503 hasConceptScore W3013582503C41625074 @default.
• W3013582503 hasConceptScore W3013582503C502942594 @default.
• W3013582503 hasConceptScore W3013582503C529278444 @default.
• W3013582503 hasConceptScore W3013582503C54355233 @default.
• W3013582503 hasConceptScore W3013582503C55493867 @default.
• W3013582503 hasConceptScore W3013582503C60903277 @default.
• W3013582503 hasConceptScore W3013582503C71924100 @default.
• W3013582503 hasConceptScore W3013582503C86803240 @default.
• W3013582503 hasConceptScore W3013582503C95444343 @default.
• W3013582503 hasConceptScore W3013582503C98274493 @default.
• W3013582503 hasLocation W30135825031 @default.
• W3013582503 hasOpenAccess W3013582503 @default.
• W3013582503 hasPrimaryLocation W30135825031 @default.
• W3013582503 hasRelatedWork W11318889 @default.
• W3013582503 hasRelatedWork W13365833 @default.
• W3013582503 hasRelatedWork W17969427 @default.
• W3013582503 hasRelatedWork W19630745 @default.
• W3013582503 hasRelatedWork W20500373 @default.
• W3013582503 hasRelatedWork W21646266 @default.
• W3013582503 hasRelatedWork W2986618 @default.
• W3013582503 hasRelatedWork W3926948 @default.
• W3013582503 hasRelatedWork W5688589 @default.
• W3013582503 hasRelatedWork W6305880 @default.
• W3013582503 isParatext "false" @default.
• W3013582503 isRetracted "false" @default.
• W3013582503 magId "3013582503" @default.
• W3013582503 workType "article" @default.